Name: SJF620
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Purity

≥98%

Solubility

Soluble in DMSO

Storage

Store at -20°C

IUPACName

3-[6-[2-[2-[2-[4-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]ethoxy]ethoxy]ethoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione

Synonyms

3-(5-{2-[2-(2-{4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl}ethoxy)ethoxy]ethoxy}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-piperidinedione; 2,6-Piperidinedione, 3-[5-[2-[2-[2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]ethoxy]ethoxy]ethoxy]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-

Boiling Point

988.1±65.0°C at 760 mmHg

Density

1.4±0.1 g/cm3

InChI Key

UJJYPBWMGIPXOE-UHFFFAOYSA-N

InChI

InChI=1S/C41H44N8O7/c42-38-36-37(27-6-8-31(9-7-27)56-30-4-2-1-3-5-30)46-49(39(36)44-26-43-38)29-14-16-47(17-15-29)18-19-53-20-21-54-22-23-55-32-10-11-33-28(24-32)25-48(41(33)52)34-12-13-35(50)45-40(34)51/h1-11,24,26,29,34H,12-23,25H2,(H2,42,43,44)(H,45,50,51)

Canonical SMILES

C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC(=C3)OCCOCCOCCN4CCC(CC4)N5C6=NC=NC(=C6C(=N5)C7=CC=C(C=C7)OC8=CC=CC=C8)N

1. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties

Alexandru D Buhimschi, Craig M Crews, Momar Toure, John Hines, Saul Jaime-Figueroa Bioorg Med Chem Lett . 2020 Feb 1;30(3):126877. doi: 10.1016/j.bmcl.2019.126877.

A new series of Proteolysis Targeting Chimeras (PROTACs) targeting Bruton's Tyrosine Kinase (BTK) was synthesized, with the goal of improving the pharmacokinetic properties of our previously reported PROTAC, MT802. We recently described the ability of MT802 to induce degradation of both wild-type and C481S mutant BTK in immortalized cells and patient-derived B-lymphocytes. However, the pharmacokinetic properties of MT802 were not suitable for further in vivo development. Therefore, we undertook a systematic medicinal chemistry campaign to overcome this issue and made a series of PROTACs with structural modifications to the linker and E3-recruiting ligand; more specifically, the new PROTACs were synthesized with different von Hippel-Lindau (VHL) and cereblon (CRBN) ligands while keeping the BTK ligand and linker length constant. This approach resulted in an equally potent PROTAC, SJF620, with a significantly better pharmacokinetic profile than MT802. This compound may hold promise for further in vivo exploration of BTK degradation.

I am curious about its application, could you tell me? thanks.

Potential applications: B-cell malignancies: SJF620 is primarily being investigated for treating B-cell malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström's macroglobulinemia. Its potent and selective BTK degradation potential makes it a promising candidate for these diseases. Other B-cell related disorders: Research is also exploring its potential in autoimmune diseases where B-cell activity is involved, such as rheumatoid arthritis and inflammatory bowel disease.

23/3/2016

Does it belongs to Btk degrader?

Yes, it is. It features two ligands: one targeting Cereblon, an E3 ubiquitin ligase protein that tags proteins for degradation by the UPS, and the other targeting Bruton's tyrosine kinase (BTK), a protein involved in B-cell signaling pathways.

20/7/2017

Could you explain to me its Potent and selective? thanks.

SJF620 shows high potency in degrading BTK, with a DC50 of 7.9 nM in cellular assays. This indicates its effectiveness at even low concentrations. Additionally, it exhibits good selectivity for BTK compared to other proteins.

8/7/2021

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂